Dr. Hualin Wang has 10+ years of research experience in the field of liver diseases. Before joining Zhimeng Biopharma, Dr. Wang was a Co-Principal Investigator (Co-PI) at Kunming University of Science and Technology, focusing on cell therapy for hepatic fibrosis.

Dr. Wang received his Ph.D. in Biochemistry and Molecular Biology from Pierre and Marie Curie University, and conducted postdoctoral research on the molecular targets of hepatocellular carcinoma (the most common type of primary liver cancer) at the University of California, San Diego (UCSD).